To determine if the high basal levels of MCL-1 and BCL-XL in CRC cells may restrict their sensitivity to BRAF inhibitor (encorafenib) induced apoptosis, we tested the effect of combining encorafenib with BH3 mimetics targeting either MCL-1 (S63845), BCL-XL (A-1331852), or BCL-2 (ABT-199) on apoptosis in BRAFV600E CRC cell lines. Here, BCL2 is linked to colorectal carcinoma.